A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applications Two scientific posters featuring results from OGM applications in cell manufacturing and bioprocessing applications will be presented at the conference SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE ...

SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in obtaining re ...

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the company's VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessment of hematol ...

财务数据和关键指标变化 - 第一季度收入为8.8百万美元,同比增长18%,剔除已停止的临床服务收入1.4百万美元,核心收入为7.3百万美元,同比增长21% [14] - OGM安装基数增加到347台,较2023年第一季度的259台增长34% [15] - 第一季度销售了8,249个流通池,同比增长58% [15] - 第一季度GAAP毛利率为32%,非GAAP毛利率为34%,分别较2023年同期的28%和30%有所提升 [16] 各条业务线数据和关键指标变化 - 公司正在推进Stratys系统的商业化,并计划在今年下半年发布对Stratys Compute的数据分析处理时间的改进 [25][26] - 公司已在第四季度2023年将预商业系统部署到现场,并最近又增加了两个客户现场,计划在2024年第三季度全面商业化离子系统 [26][27] 各个市场数据和关键指标变化 - 第一季度OGM相关论文发表量达到97篇,同比增长83%,这对于推动OGM在各利益相关方中的应用很有帮助 [30] - 公司已提交第三次申请获得OGM的CPT 1类编码,这表明取得了进展,正在等待5月9日的编辑委员会会议结果 [32][33] 公司战略和发展方向及行业竞争 - 公司正在执行成本节约和战略生产力举措,以提高敏捷性、提高效率并优先投资于最有潜力推动OGM在多个终端市场的采用和使用的机会 [12] - 公司正在推进Stratys、VIA软件和离子系统等产品的开发和商业化,旨在实现OGM的规模化应用 [25][26][27][28] - 公司获得了一项900,000欧元的研究创新基金,用于在荷兰拉德堡大学医学中心推广OGM的常规使用 [29] 管理层对经营环境和未来前景的评论 - 管理层认为当前资本市场环境存在挑战,但对OGM技术在细胞遗传学领域的转型能力充满信心 [35] - 公司维持2024年全年收入37-41百万美元的指引,并预计2024年第二季度收入在7.8-8.2百万美元之间 [34]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: ...

Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress • Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023 • Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023 • Sold 8,249 nanochannel array flowcells in Q1 2024, which represents a 58% increase over the number of flowcells sold in Q1 2023 • Efforts to reduce cash burn and operating expense continued with the March 2024 announce ...

Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023 Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023 Sold 8,249 nanochannel array flowcells in Q1 2024, which represents a 58% increase over the number of flowcells sold in Q1 2023 Efforts to reduce cash burn and operating expense continued with the March 2024 announcement of expanded cost savings initiatives; since the initial cost savings initiative announ ...

Carvana (NYSE:CVNA) - 投资者对高潜力股放弃，担心利率上升过度[1] - 短卖者认为高利率将对负债严重、亏损的公司造成巨大压力[1] - Carvana (NYSE:CVNA)股价飙升917%，是成功的反向投资案例[1] Bionano (NASDAQ:BNGO) - Bionano (NASDAQ:BNGO)开发了一种名为光学基因组映射（OGM）的DNA分析方法[2] - OGM比标准DNA分析工具更准确，对白血病患者等有更适合的治疗[2] - OGM比测序更准确，能分析更多碱基对[3] - 多家知名医院和制药公司正在使用OGM[4] - BNGO股票可能受益于美国医学协会（AMA）批准OGM的决定[5] SolarEdge (NASDAQ:SEDG) - SolarEdge (NASDAQ:SEDG)的财务业绩在过去几个季度下滑，但预计未来会有改善[7] - SEDG预计其每股收益将在“正常化”环境下反弹至3美元，分析师更看好，预计2025年每股收益将达到4.21美元[9] - 多家分析师预计太阳能行业将受益于美国电力消费增加[11] Xpeng (NASDAQ:XPEV) - Xpeng (NASDAQ:XPEV)电动汽车交付量同比增长29%，新车型X9 EV在中国市场领先[12] - XPEV的ADAS产品XNGP的渗透率不断增加，扩展至泰国、新加坡、马来西亚和德国[14] - Xpeng与大众汽车（OTCMKTS:VLKAF）的合作关系扩大，对其长期前景有利[15]

Bionano与迪安基因合作 - Bionano与杭州迪安基因生物技术有限公司达成战略合作伙伴关系，旨在推出首个将OGM和AI染色体核型分析相结合的细胞遗传学工作流程[1] - 迪安基因已从中国国家药品监督管理局获得Bionano的OGM试剂的I类注册和批准，并计划将Saphyr™仪器注册给NMPA用于生殖健康临床使用[3] Diagens的期望 - Diagens期望开发的细胞遗传学工作流程将结合AI分析和OGM，作为一种转变性方法来检测与反复流产相关的致病结构变异(SVs)以及其他可能影响妊娠或导致新生儿发育问题的重要基因组变异[2] Bionano总裁的表态 - Bionano的总裁兼首席执行官Erik Holmlin表示，将OGM和AI结合在细胞遗传学工作流程中的转变性方法将推动在宪法性遗传疾病研究中的SV检测，有望帮助中国大量寻求生殖健康支持的人群，包括考虑怀孕的个体的遗传分析、体外受精胚胎的植入前分析以及其他产前和产后基因组分析[5]

融资计划 - Bionano Genomics, Inc.宣布将以1.145美元的价格进行注册直接发行，预计募集资金约为1000万美元[1] - 公司计划将募集的净收益用于一般企业用途，包括营运资金、研发费用、偿还或赎回现有债务和资本支出[2] 产品说明 - Bionano Genomics, Inc.的OGM产品仅供研究使用，不用于诊断程序[7]